- Home
- VIVS
as 06-27-2025 4:00pm EST
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 64.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.41 - $21.96 | Next Earning Date: | 07-07-2025 |
| Revenue: | $144,000 | Revenue Growth: | 32.11% |
| Revenue Growth (this year): | 42.38% | Revenue Growth (next year): | 15.42% |
Latest VivoSim Labs Inc. Common Stock News
VIVS Breaking Stock News: Dive into VIVS Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
XPeng or NIO: Which Chinese EV Stock Looks Stronger Now?
GlobeNewswire
2 months ago
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
GlobeNewswire
2 months ago
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
Compare VIVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIVS VivoSim Labs Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.